Ratings Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Delayed Hong Kong S.E. Other stock markets 04:08:20 2024-05-14 am EDT			5-day change	1st Jan Change
17.58 ^HKD	+2.09%		+2.21%	+26.47%

May. 14	Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China	MT
May. 06	Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy	MT

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company appears highly valued given the size of its balance sheet.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SHANGHAI HENLIUS BIOTECH, INC.	+26.47%	1.2B	-
CSL LIMITED	-1.20%	89.37B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B	A-
BIOGEN INC.	-12.32%	32.81B	B-
UCB	+52.41%	25B	A
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.29B	C
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.61B	B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.49B	D+
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.98B	B+
INNOVENT BIOLOGICS, INC.	-7.72%	8.23B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes